I just heard that the PSP Trial Platform’s enrollment kick-off, set to happen this month, has been postponed to sometime later this year. 

You can read more about the PTP in this blog post of mine and on www.clinicaltrials.gov.  The delay, I’m told, is that the trial organizers and the sponsor of one of the three drugs have yet to nail down certain administrative issues.  That sponsor is Alzprotect, a French company, and its PSP drug is AZP-2006, an oral drug addressing abnormal tau disposal and inflammation.  The two drugs fully in place are AADvac1, a subcutaneously injected anti-tau vaccine from Axon; and LM11A-31, an orally administered nerve growth factor modulator from PharmatrophiX.   

A bit of good news is that the FDA has given the green light to the Alprotect drug to start its participation in the PTP trial.  That had been one of the causes of the delay, and now only those admin issues remain. 

So, the trial from start of this Phase II trial (the PTP) to full FDA approval, which if all goes well would have taken at least four years, will now need a few months longer.  But the PTP’s participating sites are enthusiastic, the financial support is in place, the underlying science is good, and the medical leadership is first-rate. I realize that these reassurances are scant comfort to those affected by PSP and their families, but they’re important.

I’ll pass along updates when I can.